Vetter Opens New Asia Pacific Office

Nov 20, 2014

Vetter, a leader in the aseptic fill and finish of injection systems, announced the opening of a new representative office in Singapore.

The new office will allow Vetter to take better advantage of the rapidly growing Asian healthcare market by increasing the presence of the company in this market. It will be staffed by Chervee Ho, Director Key Account Management Asia Pacific. The company’s Asian customers were previously handled by the German-based departments of Key Account Management, Project Management and Customer Service. Ms. Ho will be responsible for supporting the German departments to better serve the existing customer base due to geographic and time proximity as well as the development of new markets.

“For more than 35 years, the name Vetter has been synonymous with high-quality aseptically pre-filled injection systems. The office in Singapore, known as a vibrant city conveniently located in the heart of the Asia Pacific region, will help to increase the awareness of our comprehensive service portfolio in the Asian market”, said chairman of the advisory board and company owner Udo J. Vetter. “With a growing market demand, Vetter responds by strengthening its global position as a strategic partner for both the development phase, and commercial manufacturing of parenteral drugs. The new location enforces that strategy within Asia”, adds managing director Peter Soelkner.

Mr. Kevin Lai, Executive Director Biomedical Sciences of the Singapore Economic Development Board, congratulated Vetter on this momentous occasion: “We are pleased that Vetter, a leading company in aseptic fill and finish, will be establishing its representative office in Singapore – its first in Asia. Vetter’s decision is a strong recognition of Singapore’s status as a global biomedical sciences hub and endorsement of our continuous efforts to build a diversified and vibrant biomedical manufacturing sector supplying medicines across the world.”

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments